Abstract
Purpose
To investigate the use of adaptive transformations to assess the parameter distributions in population modeling.
Methods
The logit, box-cox, and heavy tailed transformations were investigated. Each one was used in conjunction with the standard (exponential) transformation for PK and PD parameters. The shape parameters of these transformations were estimated to allow the parameter distributions to more accurately resemble a wider range of parameter distributions. The transformations were tested both in simulated settings where the true distributions were known and in 30 models developed from real data.
Results
In the simulated setting the transformations were better than the standard lognormal distribution at characterizing the true distributions. Improvement could also be seen in objective function value (OFV) and in simulation based diagnostics. In the real datasets, significant model improvement based on OFV could be seen in 22, 18, and 22 out of the 30 models for the three transformations respectively.
Conclusion
Transformations with estimated shape parameters are a promising approach to relax the often erroneous assumption of a known shape of the parameter distribution. They offer a simple and straightforward way of handling and characterizing parameter distributions.
Similar content being viewed by others
References
Bressolle F, Gomeni R. Predictive performance of a semiparametric method to estimate population pharmacokinetic parameters using NONMEM. J Pharmacokinet Biopharm. 1998;26:349–61.
Davidian M, Gallant AR. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. J Pharmacokinet Biopharm. 1992;20:529–56.
Fattinger KE, Sheiner LB, Verotta D. A new method to explore the distribution of interindividual random effects in non-linear mixed effects models. Biometrics. 1995;51:1236–51.
Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231–252.
Wahlby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn. 2002;29:251–269.
Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.
Jonssonand EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64.
Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003;55:44–551.
Zingmark PH, Edenius C, Karlsson MO. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol. 2004;58:378–89.
Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F. Application of population pharmacokinetics to cladribine. BMC Pharmacol. 2005;5:4.
Cullberg M, Eriksson UG, Wahlander K, Eriksson H, Schulman S, Karlsson MO. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther. 2005;77:279–90.
Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46:1204–11.
Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207–46.
Rydberg T, Jonsson A, Karlsson MO, Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1997;43:373–81.
Iliadis MC, Bruno R, Lacarelle B, Cosson V, Mandema JW, Le Roux Y, et al. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data. J Pharmacokinet Biopharm. 1992;20:653–69.
Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98:14–1723.
Vozeh S, Aarons L, Wenk M, Weiss P, Follath F. Population pharmacokinetics of tobramycin. Br J Clin Pharmacol. 1989;28: 305–14.
Karlssonand MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735–50.
Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol. 2006;62:727–35.
Troconiz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO. Population pharmacodynamic modeling of levodopa in patients with Parkinson’s disease receiving entacapone. Clin Pharmacol Ther. 1998;64:106–16.
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.
Hamren B, Bjork E, Sunzel M, Karlsson M. Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment. Clin Pharmacol Ther (2008).
Lindemalm S, Liliemark J, Gruber A, Eriksson S, Karlsson MO, Wang Y, et al. Comparison of cytotoxicity of 2-chloro- 2′-arabino-fluoro-2′-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica. 2003;88:324–2.
McNay JL, Brynne L, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. Br J Clin Pharmacol. 2001;51:35–43.
Hornestam B, Jerling M, Karlsson MO, Held P. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol. 2003;58:747–55.
Hamrén, B. Safety and Efficacy Modelling in Anti-Diabetic Drug Development., Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Vol. Doctor, Uppsala University, Uppsala, 2008, p. Paper II.
Sadray S, Jonsson EN, Karlsson MO. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res. 1999;16:1260–5.
Sheiner LB, Beal SL. NONMEM Users Guide. (1992).
Acknowledgements
Moa Grahm for technical assistance and Johnson & Johnson Pharmaceutical Research & Development for sponsoring the doctoral studies of Klas Petersson.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix I. Assessment of the Type I Error Rates
When building models using maximum likelihood as in NONMEM, the likelihood ratio test is often used to test if the inclusion of a new parameter that is to be estimated into the model is statistically significant. Under asymptotic conditions the likelihood ratio statistic is χ2 distributed, which implies that a drop in OFV needs to be larger than 3.84 for an inclusion of a new parameter, corresponding to one degree of freedom, to be statistically significant at p < 0.05 (28). Monte Carlo simulations were performed to investigate if the likelihood ratio statististic of the shape parameters estimated in these transformations are χ2 distributed with the same number of degrees of freedom as additional parameters estimated, which would be in accordance with statistical theory. This kind of investigation would also test the robustness of the likelihood ratio test as it has been done with other model misspecifications (4,5).
Datasets were simulated from a model with a constant rate infusion at steady state, thus parameterized only with one structural parameter; CL, modeled with interindividual variability, this simple model was chosen for runtime reasons. Simulations were performed with transformations included, but the shape parameters set to values that would give no change in the shape of the distributions. These values were 0.00001 for box-cox, 0.5 and 4 for the two parameters of the logit transformation, and 0 for HTT. The simulation settings were altered and combined with respect to number of individuals and number of observations. The number of individuals ranged between 25 and 500, and observations ranged between 2 and 19. For each combination, 1000 datasets were simulated. The datasets were then estimated both with the full model with transformation as well as with the reduced model, i.e. the standard lognormal distribution. The OFV values from the estimation with both models were then compared for each simulated dataset, and the drop in OFV which produced an error rate of 5% was calculated. Expected values would be 3.84 for box-cox and HTT and 5.99 for logit because of its two parameters.
The results of the assessment of the type I error rates through simulations showed that the cut-off values for inclusion of a transformation of a parameter distribution were drops in OFV of 7, 4, and 5 for the logit, box-cox, and HT transformations, respectively. These values do not differ to any large extent from the nominal values of 3.84 and 5.99. These error rates were considered to be stable from 50 individuals and up. At lower numbers of individuals (25) the values are slightly elevated (see Table VI, which shows the average cut-off values of from varying the number of observations per individual).
Appendix II Examples of NM-TRAN Code
Logit transformation
TVCL=THETA(1)
LGPAR1 = THETA(2)
LGPAR1 = THETA(3)
PHI = LOG(LGPAR1/(1-LGPAR1))
PAR1 = EXP(PHI+ETA(1))
ETATR = (PAR1/(1+PAR1)-TVTH)*LGPAR2
CL=TVCL*EXP(ETATR)
Box-Cox transformation
TVCL=THETA(1)
BXPAR=THETA(2)
PHI = EXP(ETA(1))
ETATR = (PHI**BXPAR-1)/BXPAR
CL=TVCL*EXP(ETATR)
Heavy tailed transformation
TVCL=THETA(1)
HTPAR=THETA(2)
ETATR=ETA(1)*SQRT(ETA(1)*ETA(1))**HTPAR
CL=TVCL*EXP(ETATR)
Rights and permissions
About this article
Cite this article
Petersson, K.J.F., Hanze, E., Savic, R.M. et al. Semiparametric Distributions With Estimated Shape Parameters. Pharm Res 26, 2174–2185 (2009). https://doi.org/10.1007/s11095-009-9931-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-009-9931-1